ACAT1 inhibitors effectively suppress tumor proliferation with elevated ACAT1 expression; conversely, diminished ACAT1 expression in the tumor microenvironment leads to MDSC accumulation, creating an immunosuppressive environment that facilitates glioblastoma progression [44]. This evidence concerns the gene ACAT1 and glioblastoma.